全文获取类型
收费全文 | 31182篇 |
免费 | 2795篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 200篇 |
儿科学 | 1123篇 |
妇产科学 | 980篇 |
基础医学 | 4216篇 |
口腔科学 | 499篇 |
临床医学 | 3942篇 |
内科学 | 5952篇 |
皮肤病学 | 374篇 |
神经病学 | 3358篇 |
特种医学 | 844篇 |
外国民族医学 | 1篇 |
外科学 | 2883篇 |
综合类 | 533篇 |
一般理论 | 48篇 |
预防医学 | 4167篇 |
眼科学 | 691篇 |
药学 | 2210篇 |
中国医学 | 36篇 |
肿瘤学 | 2005篇 |
出版年
2023年 | 213篇 |
2022年 | 260篇 |
2021年 | 615篇 |
2020年 | 424篇 |
2019年 | 685篇 |
2018年 | 746篇 |
2017年 | 563篇 |
2016年 | 598篇 |
2015年 | 673篇 |
2014年 | 959篇 |
2013年 | 1449篇 |
2012年 | 2033篇 |
2011年 | 2124篇 |
2010年 | 1163篇 |
2009年 | 1088篇 |
2008年 | 1736篇 |
2007年 | 1979篇 |
2006年 | 1874篇 |
2005年 | 1804篇 |
2004年 | 1795篇 |
2003年 | 1637篇 |
2002年 | 1532篇 |
2001年 | 492篇 |
2000年 | 452篇 |
1999年 | 427篇 |
1998年 | 343篇 |
1997年 | 289篇 |
1996年 | 235篇 |
1995年 | 237篇 |
1994年 | 199篇 |
1993年 | 204篇 |
1992年 | 298篇 |
1991年 | 297篇 |
1990年 | 267篇 |
1989年 | 255篇 |
1988年 | 204篇 |
1987年 | 233篇 |
1986年 | 188篇 |
1985年 | 217篇 |
1984年 | 186篇 |
1983年 | 204篇 |
1982年 | 179篇 |
1981年 | 175篇 |
1980年 | 151篇 |
1979年 | 165篇 |
1976年 | 152篇 |
1975年 | 141篇 |
1974年 | 179篇 |
1973年 | 165篇 |
1972年 | 141篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
991.
Miranda So Jonathan Hand Graeme Forrest Stephanie M. Pouch Helen Te Monica I. Ardura Rachel M. Bartash Darshana M. Dadhania Jeffrey Edelman Dilek Ince Margaret R. Jorgenson Sarah Kabbani Erika D. Lease Deborah Levine Linda Ohler Gopi Patel Jennifer Pisano Michael L. Spinner Lilian Abbo Elizabeth C. Verna Shahid Husain 《American journal of transplantation》2022,22(1):96-112
Antimicrobial stewardship programs (ASPs) have made immense strides in optimizing antibiotic, antifungal, and antiviral use in clinical settings. However, although ASPs are required institutionally by regulatory agencies in the United States and Canada, they are not mandated for transplant centers or programs specifically. Despite the fact that solid organ transplant recipients in particular are at increased risk of infections from multidrug-resistant organisms, due to host and donor factors and immunosuppressive therapy, there currently are little rigorous data regarding stewardship practices in solid organ transplant populations, and thus, no transplant-specific requirements currently exist. Further complicating matters, transplant patients have a wide range of variability regarding their susceptibility to infection, as factors such as surgery of transplant, intensity of immunosuppression, and presence of drains or catheters in situ may modify the risk of infection. As such, it is not feasible to have a “one-size-fits-all” style of stewardship for this patient population. The objective of this white paper is to identify opportunities, risk factors, and ASP strategies that should be assessed with solid organ transplant recipients to optimize antimicrobial use, while producing an overall improvement in patient outcomes. We hope it may serve as a springboard for development of future guidance and identification of research opportunities. 相似文献
992.
Impact of the U.S. Food and Drug Administration's Safety‐Related Announcements on the Use of Bisphosphonates After Hip Fracture
下载免费PDF全文
![点击此处可从《Journal of bone and mineral research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Seoyoung C Kim Dae Hyun Kim Helen Mogun Wesley Eddings Jennifer M Polinski Jessica M Franklin Daniel H Solomon 《Journal of bone and mineral research》2016,31(8):1536-1540
The U.S. Food and Drug Administration (FDA) issued several announcements related to potential risk of bisphosphonates including osteonecrosis of the jaw (2005), atrial fibrillation (2007), and atypical femur fracture (2010). We aimed to evaluate the impact of three FDA drug safety announcements on the use of bisphosphonates in patients with hip fracture using claims data from a U.S. commercial health plan (2004‐2013). We calculated the proportion of patients in each quarter who received a bisphosphonate or other osteoporosis medication in the 6 months following hospitalization for hip fracture. Segmented logistic regression models examined the time trends. Among 22,598 patients with hip fracture, use of bisphosphonate decreased from 15% in 2004 to 3% in the last quarter of 2013. Prior to the 2007 announcement, there was a 4% increase in the odds of bisphosphonate use every quarter (OR 1.04; 95% CI, 1.02 to 1.07). After the 2007 announcement, there was a 4% decrease in the odds of bisphosphonate use (OR 0.96; 95% CI, 0.93 to 0.99) every quarter. The announcement in 2007 was associated with a significant decline in the rate of change of bisphosphonate uses over time (p < 0.001), but no impact on other osteoporosis medication use (p = 0.2). After the 2010 announcement, the odds of bisphosphonate use continued to decrease by 4% (OR 0.96; 95% CI, 0.94 to 0.98) each quarter and the odds of other osteoporosis medication use remained stable over time (OR 0.99; 95% CI, 0.96 to 1.02). The FDA safety announcement related to atrial fibrillation in 2007 was significantly associated with a decrease in bisphosphonate use among patients with hip fracture. © 2016 American Society for Bone and Mineral Research. 相似文献
993.
994.
Committed to work but vulnerable: self‐perceptions and mental health in NEET 18‐year olds from a contemporary British cohort
下载免费PDF全文
![点击此处可从《Journal of child psychology and psychiatry, and allied disciplines》网站下载免费的PDF全文](/ch/ext_images/free.gif)
995.
Stress Mediates the Relationship Between Past Drug Addiction and Current Risky Sexual Behaviour Among Low‐income Women
下载免费PDF全文
![点击此处可从《Stress and health》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Z. Helen Wu Howard Tennen G. M. Monawar Hosain Emil Coman Jerry Cullum Abbey B. Berenson 《Stress and health》2016,32(2):138-144
This study examined the role of stress as a mediator of the relationship between prior drug addiction and current high‐risk sexual behaviour. Eight hundred twenty women aged 18 to 30 years, who received care at community‐based family planning clinics, were interviewed using the Composite International Diagnostic Interview and the Sexual Risk Behavior Assessment Schedule. They also completed the brief version of the Self‐Control Scale as a measure of problem‐solving strategies and measures of recent stressful events, daily hassles and ongoing chronic stress. Regardless of addiction history, stress exposure during the previous 12 months was associated with risky sexual behaviour during the previous 12 months. Structural equation modelling revealed that 12‐month stress levels mediated the relationship between past drug addiction and 12‐month high‐risk sexual behaviours, as well as the negative relationship between problem‐solving strategies and high‐risk sexual behaviours. Problem‐solving strategies did not moderate the relationship between drug addiction and high‐risk sexual behaviours. These findings suggest that stress management training may help reduce risky behaviour among young, low‐income women Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
996.
Dimitrios Karavias Ioannis Maroulis Helen Papadaki Charalambos Gogos Stavros Kakkos Dionissios Karavias Vasiliki Bravou 《Journal of gastrointestinal surgery》2016,20(3):568-579
Background
Genomic instability is a common feature in hepatocellular carcinoma. Deregulation of replication licensing factors has been shown to trigger DNA damage response contributing to genomic instability. Overexpression of DNA replication licensing factors chromatin licensing and DNA replication factor 1 (CDT1) and minichromosome maintenance complex component 7 (MCM7) has been previously reported in several human cancers. The aim of the present study was to evaluate the expression and prognostic significance of CDT1 and MCM7 in association with DNA damage response markers and p53 in patients with hepatocellular carcinoma.Methods
Expression of CDT1, MCM7, p-H2A histone family member X (H2AX), phospho-ataxia telangiectasia-mutated (ATM)/ataxia telangiectasia rad3-related (ATR) substrate, and p53 was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded surgical specimens from 111 patients who underwent hepatectomy for hepatocellular carcinoma. Statistical analysis was performed to evaluate associations between the studied proteins, clinicopathological parameters, and patient survival.Results
CDT1 expression correlated with p-H2AX (p?=?0.038), while MCM7 correlated with p-H2AX and phospho-ATM/ATR substrate (p?<?0.001). Increased CDT1 expression was associated with higher tumor grade (p?=?0.006) and tumor-node-metastasis (TNM) stage (p?=?0.033). High CDT1 expression correlated significantly with reduced overall survival (60.8 and 26.5 % vs 82.8 and 53.0 %, for low CDT1 expression, at 2 and 5 years, respectively, p?=?0.012) and was identified by multivariate analysis as an independent predictor of poor overall survival (p?=?0.049).Conclusions
Overexpression of CDT1 and MCM7 in hepatocellular carcinoma correlates with DNA damage response, and CDT1 overexpression is a significant prognostic biomarker in hepatocellular carcinoma.997.
Guillaume?Passot Bruno?C.?Odisio Daria?Zorzi Armeen?Mahvash Sanjay?Gupta Michael?J.?Wallace Bradford?J.?Kim Suguru?Yamashita Claudius?Conrad Thomas?A.?Aloia Jean-Nicolas?Vauthey Yun?Shin?ChunEmail author 《Journal of gastrointestinal surgery》2016,20(6):1173-1178
Background
The risk of colorectal liver metastases (CLM) disappearing on cross-sectional imaging has increased with advances in preoperative chemotherapy, but <50 % of disappearing CLM demonstrate complete pathological response.Objective
The aim of this study was to evaluate the role of fiducial marker placement before potentially curative treatment of CLM at risk of disappearing with chemotherapy.Methods
All consecutive patients who underwent fiducial placement for tracking of CLM at a tertiary center were reviewed.Results
Among 1377 patients undergoing CLM resection between 2005 and 2015, 35 patients underwent fiducial placement. Three patients were excluded due to disease progression. The study population comprised 32 patients who underwent fiducial placement in 41 CLM. Among the 41 marked CLM, 34 (83 %) were located >10 mm deep in the liver parenchyma, 25 (61 %) were in the right liver, and median size was 12 mm (range, 6–20 mm). No complication occurred after fiducial placement. After chemotherapy, 19 (46 %) of the 41 marked metastases disappeared on cross-sectional imaging. All fiducial-tracked CLM were treated with resection (n?=?31) or ablation (n?=?10). After median follow-up of 14 months (range, 0–64 months), no local recurrences were observed.Conclusion
Fiducial placement represents a safe procedure that facilitates accurate localization for resection or ablation of small CLM at risk of disappearing with chemotherapy.998.
Use of Population‐based Data to Demonstrate How Waitlist‐based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
D. S. Goldberg B. French G. Sahota A. E. Wallace J. D. Lewis S. D. Halpern 《American journal of transplantation》2016,16(10):2903-2911
Liver allocation policies are evaluated by how they impact waitlisted patients, without considering broader outcomes for all patients with end‐stage liver disease (ESLD) not on the waitlist. We conducted a retrospective cohort study using two nationally representative databases: HealthCore (2006–2014) and five‐state Medicaid (California, Florida, New York, Ohio and Pennsylvania; 2002–2009). United Network for Organ Sharing (UNOS) linkages enabled ascertainment of waitlist‐ and transplant‐related outcomes. We included patients aged 18–75 with ESLD (decompensated cirrhosis or hepatocellular carcinoma) using validated International Classification of Diseases, Ninth Revision (ICD‐9)–based algorithms. Among 16 824 ESLD HealthCore patients, 3‐year incidences of waitlisting and transplantation were 15.8% (95% confidence interval [CI] : 15.0–16.6%) and 8.1% (7.5–8.8%), respectively. Among 67 706 ESLD Medicaid patients, 3‐year incidences of waitlisting and transplantation were 10.0% (9.7–10.4%) and 6.7% (6.5–7.0%), respectively. In HealthCore, the absolute ranges in states' waitlist mortality and transplant rates were larger than corresponding ranges among all ESLD patients (waitlist mortality: 13.6–38.5%, ESLD 3‐year mortality: 48.9–62.0%; waitlist transplant rates: 36.3–72.7%, ESLD transplant rates: 4.8–13.4%). States' waitlist mortality and ESLD population mortality were not positively correlated: ρ = ?0.06, p‐value = 0.83 (HealthCore); ρ = ?0.87, p‐value = 0.05 (Medicaid). Waitlist and ESLD transplant rates were weakly positively correlated in Medicaid (ρ = 0.36, p‐value = 0.55) but were positively correlated in HealthCore (ρ = 0.73, p‐value = 0.001). Compared to population‐based metrics, waitlist‐based metrics overestimate geographic disparities in access to liver transplantation. 相似文献
999.
Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease,achalasia and hypertension
下载免费PDF全文
![点击此处可从《Clinical genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S. Wallace D.‐C. Guo E. Regalado L. Mellor‐Crummey M. Bamshad D.A. Nickerson R. Dauser N. Hanchard R. Marom E. Martin V. Berka I. Sharina V. Ganesan D. Saunders S.A. Morris D.M. Milewicz 《Clinical genetics》2016,90(4):351-360
Moyamoya disease (MMD) is a progressive vasculopathy characterized by occlusion of the terminal portion of the internal carotid arteries and its branches, and the formation of compensatory moyamoya collateral vessels. Homozygous mutations in GUCY1A3 have been reported as a cause of MMD and achalasia. Probands (n = 96) from unrelated families underwent sequencing of GUCY1A3. Functional studies were performed to confirm the pathogenicity of identified GUCY1A3 variants. Two affected individuals from the unrelated families were found to have compound heterozygous mutations in GUCY1A3. MM041 was diagnosed with achalasia at 4 years of age, hypertension and MMD at 18 years of age. MM149 was diagnosed with MMD and hypertension at the age of 20 months. Both individuals carry one allele that is predicted to lead to haploinsufficiency and a second allele that is predicted to produce a mutated protein. Biochemical studies of one of these alleles, GUCY1A3 Cys517Tyr, showed that the mutant protein (a subunit of soluble guanylate cyclase) has a significantly blunted signaling response with exposure to nitric oxide (NO). GUCY1A3 missense and haploinsufficiency mutations disrupt NO signaling leading to MMD and hypertension, with or without achalasia. 相似文献
1000.
Briony Hill Helen Skouteris Matthew Fuller-Tyszkiewicz Skye McPhie 《Journal of behavioral medicine》2016,39(5):793-803
This study evaluated: (1) the efficacy of a health coaching (HC) intervention designed to prevent excessive gestational weight gain (GWG); and (2) whether there were improved psychological, motivational, and behavioural outcomes for women in the HC intervention compared to a “usual care” control group. In this quasi-experimental study, 267 pregnant women ≤18 weeks gestation were recruited between August 2011 and June 2013 from two hospital antenatal clinics in Melbourne, Australia. Intervention women received four individual HC and two group HC/educational sessions informed by theories of behaviour change. Women completed questionnaires assessing psychological, motivational and behavioural outcomes at 16–18 (baseline) and 33 (post-intervention) weeks gestation. Weight measures were collected. Compared to usual care, the intervention did not limit GWG or prevent excessive GWG. However, HC women reported greater use of active coping skills post-intervention. Despite lack of success of the HC intervention, given the risks associated with excessive weight gain in pregnancy, health professionals should continue to recommend appropriate GWG. 相似文献